Cette liste est basée sur les listes de surveillance des personnes sur Stock Events qui suivent PRLD. Il ne s'agit pas d'une recommandation d'investissement.
Sur la base de 2 notations au cours des 6 derniers mois. Il ne s'agit pas d'une recommandation d'investissement.
Acheter
0%
Détenir
100%
Vendre
0%
À propos de nous
Health Technology
Biotechnology
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2, which is in preclinical stage for multiple genomically selected cancers; PRT3645, a brain penetrant molecule that potently and selectively targets CDK4/6; and PRT-K4 that is in preclinical stage for solid tumors. The company was incorporated in 2016 and is headquartered in Wilmington, Delaware.